Xoft wins Canadian approval for Axxent electronic brachytherapy system

Xoft, a developer of electronic brachytherapy systems, has received a medical device license from the Medical Devices Bureau of Health Canada to sell and market the Axxent electronic brachytherapy system.

According to Xoft, the electronic brachytherapy (eBx) treatment platform is designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings under the supervision of a radiation oncologist to help reduce recurrence of cancer and improve survival.

Use of the Axxent eBx system allows physicians to target cancer effectively and expands the ability to provide radiation therapy in remote locations, the company said.

Xoft has also received certification from the International Organization for Standardization covering the design, development and manufacture of the Axxent electronic brachytherapy system and its components.

Michael Klein, president and CEO of Xoft, said: With this approval from Health Canada, we are proud to make this critical cancer treatment that can be delivered in virtually any standard medical exam room rather than in heavy lead-shielded vaults available to patients outside the US.

Combined with recent FDA clearances for new treatment applications, this approval is another significant milestone supporting Xoft’s mission of expanding the number of patients who can access radiation therapy and can dramatically benefit from it.